China News Service, Foshan, September 30 (Reporter Cheng Jingwei) The Guangdong Provincial Drug Administration and the Foshan Municipal People's Government recently signed the "Framework Agreement for Jointly Promoting the High-quality Development of Foshan's Biomedical Industry" (hereinafter referred to as the "Agreement"), proposing A series of specific measures and policy service guarantee measures to support Foshan's pilot in the field of biopharmaceutical industry.
Among them, in Yundonghai Biomedical Industrial Park (hereinafter referred to as "Yundonghai Industrial Park"), a public service platform for the biopharmaceutical industry will be jointly built, and the Guangdong Provincial Drug Administration Review and Certification Center, Guangdong Provincial Drug Inspection Institute, and Guangdong Provincial Medical Devices will be jointly established. The platforms of institutions such as the Quality Supervision and Inspection Institute are extended to Sanshui, Foshan, etc.
It is reported that Yundonghai Industrial Park is located in the core area of Sanshui District and is one of the top ten innovative and leading characteristic manufacturing parks in Foshan.
With the blessing of this provincial policy, the development of Sanshui biopharmaceutical industry is expected to comprehensively improve the development level, build a first-class and world-class new industrial platform of 10,000 mu and 100 billion yuan in the Bay Area, and become a new growth pole of biomedicine in the Greater Bay Area.
According to reports, the Foshan Branch of the Evaluation and Certification Center of the Guangdong Provincial Drug Administration, the Drug Safety Evaluation Center of the Guangdong Provincial Institute of Drug Control, and the Foshan Laboratory of the Guangdong Provincial Institute of Medical Device Quality Supervision and Inspection will be extended to the Yundonghai Industrial Park.
On the one hand, relevant platforms will support the creation of a biomedical science and technology achievement transformation base, a biomedical science and technology international cooperation innovation zone, and promote the construction of a whole industry chain and life cycle management service platform of “innovative research and development-registration review-supervision and management-industrial services”; At the same time, it provides a green channel for priority review and approval, administrative licensing, testing and inspection, and safety evaluation for enterprises settled in Yundonghai Biomedical Industrial Park.
On the other hand, the relevant platforms will provide precise services for enterprises, strengthen the guidance on the registration and application of innovative medical devices by enterprises, explore interventions from the research and development stage, and speed up the process of product review and approval.
The "Agreement" shows that the Guangdong Provincial Drug Administration and the Foshan Municipal People's Government will jointly promote the implementation of the "Hong Kong-Macao Pharmaceutical Machinery Link" in Foshan, and promote the local production of Hong Kong and Macao drugs and medical devices in the Greater Bay Area.
Guangdong's "14th Five-Year Plan" clearly proposes to accelerate the development of the biopharmaceutical industry and form a competitive advantage in the fields of biological drugs, chemical drugs, modern Chinese medicine, high-end medical equipment, and medical services.
As we all know, Foshan Sanshui has a unique location advantage in the Greater Bay Area, and has a two-way advantage in facing the domestic and international markets.
As the "axis" of the Sanshui biomedical industry map, Yundonghai Industrial Park has 10,000 mu of industrial development space, 10,000 mu of national wetland park, and 10,000 mu of natural ecological green core. It is the only developable land in the Guangdong-Hong Kong-Macao Greater Bay Area. biopharmaceutical industrial park.
At present, Yundonghai Industrial Park has introduced 2 projects exceeding 10 billion yuan, 1 project exceeding 5 billion yuan, more than 100 reserve projects, and the total amount of intended investment exceeds 80 billion yuan.
With the establishment of the scientific and technological achievements transformation platform, it will further promote the integration of clinical medicine into the whole process of biomedicine and medical device research and development. Yundonghai Industrial Park is expected to become an important part of the preemptive layout of future industries.
"Sanshui has obvious location advantages and superimposed advantages such as government support. It is an excellent virgin land for the development of the biopharmaceutical industry." Xie Jiasheng, CEO of Guangdong Medical Valley, believes that they chose to develop in Sanshui because they are optimistic about the development potential and development of Sanshui. Advantage.
(Finish)